RTP Mobile Logo
Select Publications

Corey J Langer, MD

Borghaei H et al. Five-year outcomes from the randomized, Phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2021;39(7):723-33. Abstract

Garon E et al. TROPION-PanTumor01: Updated results from the NSCLC cohort of the Phase I study of datopotamab deruxtecan in solid tumors. IASLC 2021;Abstract MA03.02.

Gogishvili M et al. EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line treatment of advanced NSCLC. ESMO 2021;Abstract LBA51.

Han B et al. DUBLIN-3 (BPI-2358-103): A global phase (ph) III trial with the plinabulin/docetaxel (plin/doc) combination vs doc in 2nd/3rd line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen. ESMO 2021;Abstract LBA48.

Johnson M et al. Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: Results from the Phase III POSEIDON study. IASLC 2021;Abstract PL02.01.

Paz-Ares LG et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-Year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol 2022;17(2):289-308. Abstract

Reck M et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 2021;6(5):100273. Abstract

Reck M et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic NSCLC with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 2021;39(21):2339-49. Abstract

Sezer A et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021;397(10274):592-604. Abstract

Socincki MA et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol 2021;16(11):1909-24. Abstract

Socinski MA et al. Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase III trials IMpower130, IMpower132, and IMpower150. ASCO 2021;Abstract 9002.

Anne S Tsao, MD, MBA

Felip E et al. Impower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in Stage IB-IIIA NSCLC. ESMO 2021;Abstract LBA9.

Forde PM et al. Nivolumab (nivo) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. AACR 2021;Abstract CT003.

Girard N et al. PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. ESMO 2021;Abstract 1171MO.

Liu SV et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021;39(6):619-30. Abstract

Martinez-Marti A et al. COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. ESMO 2021;Abstract LBA42.

Paz-Ares L et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase III CASPIAN study. ESMO 2021;Abstract LBA61.

Paz-Ares L et al. Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: Phase III randomized ATLANTIS trial. IASLC 2021;Abstract PL02.03.

Peters S et al. First-line nivolumab (nivo) plus ipilimumab (ipi) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. ESMO 2021;Abstract LBA65.

Spicer J et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (nivo) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8503.

Spigel DR et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. ASCO 2021;Abstract 8511.

Tsao A et al. S1619 A trial of neoadjuvant cisplatin-pemetrexed with atezolizumab in combination and maintenance for resectable pleural mesothelioma. ISALC 2021;Abstract OA13.01.

Wakelee HA et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8500.

Weiss J et al. Effects of trilaciclib on chemotherapy- induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: Pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021:22(5):449-60. Abstract